Related by context. All words. (Click for frequent words.) 72 prognostic markers 72 molecular biomarkers 71 predictive biomarker 71 diagnostic biomarkers 71 ALK inhibitors 70 epigenetic therapies 70 diagnostic biomarker 70 biomarker identification 70 validate biomarkers 69 MEK inhibitors 69 DNA methylation biomarkers 69 JAK2 inhibitor 69 therapeutic monoclonal antibody 68 small molecule activators 68 eTag assays 68 druggable targets 68 genomic biomarkers 68 biomarker assays 68 pharmacogenetic testing 68 gefitinib Iressa 68 genetic biomarkers 68 CYT# potent vascular disrupting 68 immunotherapeutic approaches 67 pharmacogenetic 67 EGFR TKIs 67 investigational therapies 67 bevacizumab Avastin ® 67 HuLuc# 67 Squalamine 67 prognostic biomarkers 67 anticancer therapies 67 AEG# 67 MyVax R 67 personalized immunotherapy 67 tyrosine kinase inhibitors 67 pertuzumab 67 biomarker 67 preclinically 66 molecular profiling 66 novel peptide 66 therapeutic monoclonal antibodies 66 small molecule inhibitors 66 therapeutic radiopharmaceuticals 66 RNAi therapeutic targeting 66 molecularly targeted 66 anti angiogenic drugs 66 Locked Nucleic Acid LNA 66 biologic pathways 66 dasatinib Sprycel 66 GPCR targets 66 biomarkers 66 oral prodrug 66 siRNA therapeutic 66 kinase inhibition 65 receptor tyrosine kinase inhibitor 65 CCR5 antagonist 65 miRNA biomarkers 65 nonviral 65 microRNA biomarkers 65 molecular abnormalities 65 EGFR inhibitors 65 proteasome inhibitors 65 JAK inhibitors 65 thalidomide Thalomid 65 prognostic biomarker 65 erlotinib Tarceva ® 65 Hedgehog inhibitor 65 IMA# 65 selective inhibitors 65 lapatinib Tykerb 65 antiviral therapies 65 BCR ABL inhibitors 65 molecular biomarker 65 Cardiotoxicity 65 siRNA therapeutics 65 demethylating agent 65 Pertuzumab 65 HSP# inhibitor 65 IAP inhibitors 65 Smac mimetics 65 methylation markers 65 kidney urologic 65 HGS# 65 Onconase 65 deforolimus 65 pharmacogenetic tests 65 alvespimycin 65 OHR/AVR# 65 JAK2 inhibitors 65 LNP formulations 65 NovaBay Aganocide compounds 65 KRAS mutation 65 antiviral compounds 65 tubulin inhibitor 65 theranostic 65 Personalized Immunotherapy 65 Theranostics 64 MGd 64 isoform selective 64 novel antibody therapeutics 64 Azedra 64 validating biomarkers 64 cediranib 64 romazarit 64 SERMs 64 eprotirome 64 therapeutic regimens 64 PI3K/mTOR 64 pharmacological chaperone 64 novel VDA molecule 64 anti angiogenic agents 64 Tyrima 64 CBLC# 64 molecularly targeted therapies 64 investigational humanized monoclonal antibody 64 imatinib resistance 64 OMP #M# 64 anticancer therapeutics 64 Deforolimus 64 VEGF inhibitors 64 imatinib Gleevec 64 companion diagnostics 64 Panzem R NCD 64 ALTTO 64 antisense inhibitors 64 myeloproliferative disorders 64 Anticalins R 64 ALN TTR 64 PDE# inhibitors 64 humanized monoclonal antibodies 64 mechanistic insights 64 genomic biomarker 64 antiplatelet therapies 64 A3 adenosine receptor 64 humanized antibody 64 proteasome inhibitor 64 Insegia 64 MMP inhibitors 64 THR beta agonist 64 SGLT2 inhibitors 64 targeting PCSK9 64 Ceflatonin 64 small molecule modulators 64 antibody MAb 64 chemopreventive agent 64 Hepatitis C Virus HCV 64 PRT# 64 PNP inhibitor 64 histone deacetylase inhibitor 64 stratify patients 64 pharmacogenomic tests 64 cancer immunotherapies 64 candidate CRLX# 64 IDO inhibitor 64 OnDose TM 64 Symadex 64 epithelial tumors 63 CTAP# Capsules 63 tumor subtypes 63 NPM1 63 Preclinical studies suggest 63 trastuzumab DM1 T DM1 63 DNA methylation markers 63 Factor VIIa 63 antiangiogenic agents 63 direct thrombin inhibitors 63 Cytolin R 63 ADME properties 63 chemotherapeutic 63 Tarvacin TM 63 Src inhibitors 63 hypoxic tumors 63 pharmacogenetic test 63 rxRNA 63 vascular disrupting agents 63 monoclonal antibody therapeutics 63 regorafenib 63 TLR9 agonists 63 PARP inhibitors 63 MyVax ® 63 PI3K/Akt pathway inhibitor 63 shRNA libraries 63 IRX 2 63 molecularly targeted therapy 63 including eniluracil ADH 63 monoclonal antibody MAb 63 Sphingomab 63 ENMD # 63 endothelin antagonists 63 predictive toxicology 63 OGeS 63 erlotinib Tarceva 63 vidofludimus 63 cMET 63 K ras mutations 63 inhibitor RG# 63 oral taxane 63 enzastaurin 63 inhibit metastasis 63 Modrenal 63 tiapamil 63 CINQUIL 63 molecular subtypes 63 kinase inhibitors 63 non nucleoside HCV 63 Hsp# inhibition 63 Xanafide 63 EGFR mutation status 63 vemurafenib 63 pathogenic mechanisms 63 FGFR 63 BRAF inhibitor 63 Corus CAD 63 vitro assay 63 breast cancer subtypes 63 FTIs 63 ONCONASE R 63 HERmark 63 HepDirect R 63 K RAS 63 NPC 1C 63 PCA3 assay 63 selective inhibition 63 Curaxin 63 depsipeptide 63 molecular imaging radiopharmaceutical 63 Triapine 63 IGF IR 63 small molecule agonists 63 refractory metastatic 63 commercialize deforolimus 63 Hemopurifier ® 63 monoclonal antibody therapies 63 BRAF inhibitors 63 Fludara ® 63 chemoresistance 63 antithrombotic agents 63 DXL# 63 Li Fraumeni 63 EGFR tyrosine kinase inhibitors 63 Anticalins 63 radiation sensitizer 63 oral antiviral 63 mTOR inhibitors 63 Intravenous CP 63 p# inhibitor 63 peptidomimetic 63 non nucleoside 63 CCR5 inhibitors 63 Campath alemtuzumab 63 efficacious treatments 63 CR# vcMMAE 63 Sphingomab TM 63 Annamycin 62 HCV polymerase 62 renin inhibitors 62 Akt inhibitor 62 Stapled Peptide 62 Aviptadil 62 CCR5 inhibitor 62 antiangiogenic therapy 62 endocrine therapies 62 epothilone 62 BRAF mutation 62 inhibit viral replication 62 VitiGam 62 polymerase inhibitors 62 IGF 1R 62 BioMAP 62 optical biosensors 62 neovascular diseases 62 XmAb# 62 nucleotide analog 62 PDGF receptor 62 NuMimetic TM 62 TPI ASM8 62 ALN PCS 62 immatics 62 CCX# 62 multitargeted 62 systemically administered 62 neratinib 62 diagnostic prognostic 62 EGFR mutations 62 TLR8 62 targeted radiotherapeutic 62 pediatric malignancies 62 metaglidasen 62 PhenoSense GT 62 Nexavar sorafenib 62 orally inhaled migraine 62 castrate resistant prostate cancer 62 splice variants 62 Quinamed 62 lumiliximab 62 LHRH receptor positive 62 myelofibrosis polycythemia vera 62 Marqibo TM 62 CCR9 antagonist 62 miRview mets 62 underlying molecular mechanisms 62 prognostic indicator 62 AMPK activators 62 cilengitide 62 prognostic indicators 62 Aurora kinase inhibitor 62 UsiRNAs 62 diagnostic assays 62 prognostic marker 62 multi kinase inhibitor 62 anti angiogenic therapy 62 PROCHYMAL 62 antiangiogenesis 62 EGFR inhibition 62 Cyclosert TM 62 Zybrestat 62 JAK inhibitor 62 OncoVex 62 Novosom 62 Fc fusion protein 62 mGlu2 3 62 unresectable tumors 62 anticancer agents 62 Mammostrat 62 aptamer therapeutics 62 delafloxacin 62 histone methyltransferases HMTs 62 imatinib Gleevec ® 62 rxRNA ™ compounds 62 epigenetic therapeutics 62 PKC# 62 HGS ETR1 62 small molecule tyrosine 62 molecular assays 62 mutational status 62 Vitaxin 62 Pseudomonas aeruginosa infections 62 orally administered inhibitor 62 VTAs 62 ospemifene 62 JAK3 62 renin inhibition 62 metastatic neuroendocrine tumors 62 tumor antigens 62 pharmacodynamic markers 62 OMAPRO 62 PITX2 62 siRNA compounds 62 ganaxolone 62 protein misfolding 62 trastuzumab Herceptin 62 gastro intestinal inflammation 62 Solazed TM 62 IMC #B 62 vivo validation 62 lymphoid tumors 62 mda 7 62 PIK3CA 62 anti CD# antibodies 62 Nanobodies 62 GMX# 62 ARIKACE ™ 62 Factor Receptor 62 anti fibrotic 62 SARMs 62 radezolid 62 Epidermal Growth Factor Receptor 62 Curaxin CBLC# 62 DCVax R 62 antisense drugs 62 compound AEZS 62 PANVAC VF 62 chemopreventive agents 62 ASONEP 62 ADI PEG 62 PROLARIS 62 immune modulating 62 JAK1 62 CDK inhibitor 62 novel antiviral therapeutics 62 antisense oligonucleotides 62 OvaRex R 62 engineered anticoagulant 62 metabolomic profiling 62 PGx 62 TroVax ® 62 PI3K inhibitors 62 histone deacetylase inhibitors 62 immunological diseases 62 ALK inhibitor 62 toxicogenomic 62 treating neuropathic pain 61 immunosuppressive therapies 61 humanised monoclonal antibody 61 OncoVEX GM CSF 61 oral JAK1 61 Nanobody ® 61 small molecule defensin 61 proteomic biomarkers 61 genomic alterations 61 protein kinase inhibitor 61 HyACT 61 DermaVir Patch 61 HQK 61 R#/MEM 61 XmAb 61 theranostics 61 generation purine nucleoside 61 vorinostat 61 protein kinase inhibitors 61 pediatric acute lymphoblastic 61 antimitotic 61 HER2 overexpression 61 DNA methyltransferases 61 Gefitinib 61 investigational pan BCR 61 mTOR inhibition 61 PXD# 61 Bucindolol 61 PTK# 61 mGluR2 NAM 61 Curaxins 61 cardiotoxic effects 61 Archexin 61 Trofex 61 pharmacological approaches 61 cellular pathways 61 endothelin antagonist 61 selective modulator 61 Fibroblast Growth Factor Receptor 61 RGB # 61 nanoviricides 61 acadesine 61 forodesine 61 immunotherapeutics 61 antihormonal 61 Smac mimetic 61 Nanobody 61 ALN TTR# 61 AttoSense 61 HER2 positive metastatic breast 61 ZACTIMA 61 dasatinib Sprycel ® 61 targeting CD# 61 somatic mutations 61 risk stratification 61 pharmacologic approaches 61 GKAs 61 nucleotide analogs 61 peptide antigens 61 BrachySil TM 61 metastatic colorectal 61 EGS# 61 TTR amyloidosis 61 Interferon beta 61 pDCs 61 trastuzumab Herceptin ® 61 pharmacodynamic biomarkers 61 Angiocept 61 Vilazodone 61 IAP inhibitor 61 EOquin 61 neuropsychiatric diseases 61 lymphoid malignancies 61 antiangiogenic 61 CA9 SCAN 61 immunotherapeutic vaccine 61 Phase IIb clinical trials 61 novel radiopharmaceuticals 61 CCR3 61 Zolinza 61 PARP inhibition 61 biomarker assay 61 vascular disrupting agent 61 gene fusions 61 biochemical profiling 61 Monoclonal antibody 61 glycopeptides 61 HuMax EGFr 61 NTDDS 61 Reverse Cholesterol Transport 61 NEUGENE 61 synthetic retinoid 61 PDE4 inhibitor 61 Temsirolimus 61 Affibody ® molecules 61 tremelimumab 61 cisplatin resistant 61 TRO# 61 Nektar proprietary 61 bioinformatic approaches 61 Myocet 61 HCV protease inhibitors 61 EGFR TKI 61 ATTR CM 61 anti infective treatments 61 Regado 61 oncolytic viruses 61 FLT3 61 Tesmilifene 61 INS# [001] 61 pharmacologic intervention 61 TLR9 agonist 61 Pralatrexate 61 HDL Mimetic Peptide 61 velafermin 61 SPC# [001] 61 hormone refractory 61 adenoviral vectors 61 Dyax phage display 61 ganetespib 61 anticancer compound 61 nucleoside analog 61 GI motility disorders 61 GSK3B 61 ChronVac C R 61 Initiate Clinical Trial 61 receptor modulators 61 TLR agonists 61 HERmark assay 61 MAbs 61 Poly ICLC 61 Dasatinib 61 elotuzumab 61 telomerase inhibitor 61 monoclonal antibodies MAbs 61 susceptibility loci 61 gene loci 61 IgG1 antibody 61 metabonomics 61 p# biomarker 61 mAbs 61 CD3 monoclonal antibody 61 PI3K AKT 61 HDACi 61 proprietary PEGylation 61 mechanistic insight 61 oncolytic 61 ADME Tox 61 biomarker validation 61 insulin sensitizers 61 antiangiogenic drugs 61 ASG 5ME 61 oral leukoplakia 61 VeriStrat 61 GSK# [002] 61 multiplex assay 61 HTS assay 61 recurrent glioblastoma multiforme 61 P2V TM 61 LHRH antagonists 61 DU #b 61 novel anticancer 61 Mutation Analysis 61 arterial thrombosis 61 HIV integrase inhibitors 61 YONDELIS R 61 targeted antifolate 61 TKM ApoB 61 fluoropyrimidine 61 novel therapeutic antibodies 61 dasatinib 61 kinase profiling 61 optimal dosing 61 TRV# [001] 61 CDP# 61 vitro ADME 61 EGFR pathway 61 thetreatment 61 SSc 61 genomic profiling 61 hepatitis C viral infection 61 antiangiogenic agent 60 obatoclax 60 ETBs 60 ATIR 60 inhibiting tumor 60 telomerase inhibitors 60 Eribulin 60 volociximab 60 TACI Ig 60 sorafenib Nexavar 60 Enzastaurin 60 DiLA2 60 immunoregulatory 60 Amplimexon 60 candidates Azedra TM 60 inhibit replication 60 protein biomarker 60 adjuvant therapies 60 QuadraSphere 60 entinostat 60 Panzem R 60 carbohydrate polymers 60 VEGF receptor 60 NEUGENE R 60 JAK3 inhibitor 60 DNA methylation biomarker 60 immunomodulators 60 rBChE 60 pharmacogenetics 60 Hepatocellular Carcinoma HCC 60 Vidaza azacitidine 60 histone deacetylase HDAC inhibitors 60 epothilones 60 MDRNA proprietary 60 immunosuppressive regimens 60 Gleevec resistant 60 therapeutic modality 60 MAGE A3 ASCI 60 Proxinium TM 60 INT# [002] 60 viral kinetics 60 identify protein biomarkers 60 poly ADP ribose polymerase 60 EGFR HER2 60 Chemetics R 60 ZOLINZA 60 Pyridorin 60 protein biomarkers 60 HDAC inhibitors 60 CCR5 antagonists 60 ATL# [002] 60 rEEG 60 lomitapide 60 2 inhibitor CYT# 60 atacicept 60 Panzem NCD 60 TRAIL receptor antibodies 60 EGFR antibodies 60 Immunotherapeutic 60 cytotoxics 60 TBC# 60 Genentech Herceptin 60 HER1 60 Pancreate 60 SLx 60 bortezomib Velcade 60 causative genes 60 selective immunoproteasome inhibitor 60 NS4A 60 acyclovir Lauriad R 60 immunomodulation 60 XmAb ® 60 delta isoform 60 NSCLC tumors 60 uric acid lowering 60 immunotherapeutic 60 ProMIS TM 60 throughput RNAi 60 Isis antisense 60 rxRNA compounds 60 psoriasis rheumatoid arthritis 60 anti tubercular 60 nucleoside analogues 60 teplizumab 60 Biomerk Tumorgrafts 60 MAbs targeting 60 ocular disorders 60 multiplexed assays 60 endophenotypes 60 stratifying patients 60 Nanobodies ® 60 ELACYT 60 paclitaxel Taxol 60 M2 subunit 60 DsiRNA 60 aerosolized KL4 surfactant 60 exon skipping 60 Janus kinase 60 immunomodulator 60 Therapeutic antibodies 60 prostate cancer CaP 60 Safinamide 60 phenotyping 60 Vidaza ® 60 refractory chronic lymphocytic 60 fusion enhancers 60 delipidation 60 Cyclosporin 60 T#I [002] 60 adenoviral 60 sd rxRNA compounds 60 hypereosinophilic syndrome 60 candidate deforolimus 60 antisense inhibitor 60 RIGScan 60 cetuximab Erbitux R 60 liposome formulations 60 optimal dosing regimens 60 radioimmunotherapy RIT 60 Alequel 60 Anticalins ® 60 retaspimycin 60 immunodeficiency disorders 60 Mipomersen 60 BAY #-# 60 candidate TNFerade biologic 60 leukotriene pathway 60 vinca alkaloid 60 Janus Kinase 60 atrasentan 60 mitochondrial toxicity 60 Phylomer ® 60 immunomodulatory therapy 60 HIF PH inhibitors 60 systemic RNAi therapeutic 60 Afatinib 60 anti CD3 60 Stat5 60 ON #.Na 60 macrolide antibiotics 60 CEQ# 60 RNA antagonists 60 serum biomarkers 60 neuronal nicotinic receptor NNR 60 tezampanel NGX# 60 ZFP Therapeutics 60 physiologic mechanisms 60 elacytarabine 60 HepDirect prodrug 60 androgen receptor antagonist 60 LEUKINE 60 Dr. Sosne 60 OXIGON TM 60 metabolite identification 60 Angiolix 60 Rasagiline 60 Anthracycline 60 superficial bladder cancer 60 antisense drug 60 HCV polymerase inhibitor 60 elvucitabine 60 antithrombotic 60 novel RNAi therapeutics 60 Syllego system 60 Epigenomics proprietary 60 CRLX# 60 tropism testing 60 Spiegelmers R 60 P#X# 60 neuroinflammation 60 SUTENT ® 60 TLR antagonists 60 TG# [003] 60 tkRNAi technology 60 TKI therapy 60 immunoregulation 60 Blinatumomab 60 IgG1 monoclonal antibody 60 castration resistant prostate cancer 60 Elotuzumab 60 potently inhibit 60 irinotecan oxaliplatin 60 antiplatelet medications 60 investigational integrase inhibitor 60 Vidofludimus 60 lintuzumab 60 cognitive enhancer 60 rxRNA TM compounds 60 Micromet BiTE 60 Aurora Kinase 60 pharmacogenomic 60 xTAG RVP 60 rNAPc2 60 histone deacetylase HDAC 60 essential thrombocythemia ET 60 Altastaph 60 ALN VSP 60 presymptomatic 60 Aplidin 60 urothelial bladder cancer 60 resolvins 60 Telatinib 60 Carfilzomib 60 Perflubutane Polymer Microspheres 60 QTinno 60 Azacitidine 60 cellular immunotherapy 60 NuroPro ® 60 interventional therapies 60 Anticalin 60 rituximab Rituxan 60 PORxin TM 60 Thiovir 60 beta secretase inhibitors 60 Aurora kinase inhibitors 60 Onalta 60 glucokinase activator 60 CDK inhibitors 60 farletuzumab 60 MEK inhibitor 60 anti angiogenic therapies 60 Reverset 60 pain palliation 60 vivo fluorescence imaging 60 multi analyte 60 therapeutic modalities 60 apoptotic pathway 60 calcineurin inhibitors 60 DEB# 60 vivo potency 60 Dapagliflozin 60 Aurora kinase 60 demonstrated antitumor activity 60 trastuzumab Herceptin R 60 Velcade bortezomib 60 HCV protease inhibitor 60 Uvidem 60 silico prediction 60 potent inhibitors 60 chemosensitivity 60 DOS# 60 fosbretabulin 60 VKORC1 60 MediGene focuses 60 tumor hypoxia 60 recombinant antibodies 60 murine models 60 tyrosine kinase inhibitor TKI 60 refractory CLL 60 taxane therapy 60 tanespimycin 60 lipid lowering therapies 60 Degarelix 60 investigational monoclonal antibody 60 cetuximab Erbitux 60 breast cancer metastasis 60 TOCOSOL Camptothecin 60 neuronal nicotinic receptors NNRs 60 protein antigens 60 genotypic resistance 60 GAP #B# 60 TLK# 60 sorafenib tablets 60 DNA intercalator 60 faropenem 60 ZFP Therapeutic 60 transfection reagents 60 Factor Xa inhibitor 60 aurora kinase 60 molecular diagnostic assays 60 radionuclide therapy 60 Selective Electrochemical Tumor Ablation 60 Fabry Disease 60 olaparib 60 molecular markers 60 Virulizin ® 60 IL# PE#QQR 60 TOCOSOL 60 next generation URAT1 60 Cx# [002] 60 phase IIb clinical 60 Adnectin 60 ADVEXIN therapy 60 insulin analogs 59 prostate cancer CRPC 59 oncolytic virus therapies 59 adrenergic regulation 59 tumor histology 59 ddRNAi 59 genetic determinants 59 antitumor effect 59 docetaxel Taxotere ® 59 canakinumab 59 Lpathomab 59 Dr. Victor Velculescu 59 CD# CEA 59 angiogenesis inhibitor 59 Zavesca r 59 differentiate squamous 59 ESBA# 59 Spiegelmers 59 Phase IIb III 59 flavopiridol 59 Apatone 59 inhibiting angiogenesis 59 PPAR gamma agonists 59 AVI NEUGENE 59 MCSP respectively 59 familial amyloidotic polyneuropathy FAP 59 tolerability pharmacokinetics 59 CD# antibody [001] 59 novel peptides 59 Anticalin R 59 Surfaxin LS 59 galiximab 59 Solazed 59 PARP inhibitor 59 Nexavar ® 59 differentiated thyroid 59 constipation OIC 59 mTOR kinase 59 etiologic factors 59 Anavex #-# 59 inactivating mutations 59 HGS ETR1 mapatumumab 59 humanised antibody 59 reslizumab 59 HCV polymerase inhibitors 59 XL# XL# 59 LungExpress Dx TM 59 Celator 59 BRAF V#E mutation 59 EP #R 59 registrational trial 59 PGL# 59 alkylating agent 59 AMN# [001] 59 peptide conjugated 59 M# rationally 59 Rigel R# 59 hematological cancers 59 antiangiogenesis therapies 59 Treg cell 59 vaccine GRNVAC1 59 Evoltra ® 59 multicenter Phase II 59 HCV protease 59 MEK inhibitor RDEA# 59 biologic therapeutics 59 APTIVUS 59 HCV infection 59 OnDose 59 ImmunoGen TAP technology 59 Breast Cancer Assay 59 Amigal 59 Manja Bouman CEO 59 Onalta TM 59 NS5b 59 Chimigen TM 59 gastrointestinal stromal tumors GISTs 59 Anticalin ® 59 OncoVEX 59 human IgG1 monoclonal 59 enzyme inhibitor 59 orally bioavailable 59 visilizumab 59 KRAS mutant 59 ErbB3 HER3 59 CB1 antagonists 59 HPV genotyping 59 NOX E# 59 mertansine 59 aerosolized AAT 59 SinuNase ™ 59 miRview TM mets 59 intranasal delivery 59 OncotypeDX 59 panobinostat 59 Tofacitinib 59 xenograft models 59 trastuzumab DM1 59 PEG SN# 59 FGFR1 59 intracellular signaling pathways 59 optimal dosing regimen 59 incyclinide 59 CXCR4 receptor 59 Foradil Aerolizer 59 RNA therapeutics 59 putative biomarkers 59 hPTH #-# 59 haematological cancers 59 Corgentin 59 novel immunotherapies 59 CRTH2 59 micafungin 59 Phase 2a clinical trials 59 blood clot dissolver 59 malignant ascites 59 acetonide FA 59 phosphorylated proteins 59 Onalta ™ 59 immunotoxins 59 mGluR5 antagonists 59 therapeutic peptide 59 AKT inhibitor 59 lung pancreatic 59 RIGScan CR 59 vinca alkaloids 59 nonclinical studies 59 liposomal formulation 59 PI3K inhibitor 59 Cylene 59 FOLOTYN ® 59 Lisofylline 59 subcutaneous formulation 59 Exelixis compounds 59 FK# 59 gene rearrangements 59 biologic therapies 59 genetic modifiers 59 RhuDex TM 59 hormone gastrin 59 Zoraxel 59 systemic fungal infections 59 DPX Survivac 59 metabolite profiling